Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Microbot Medical ( (MBOT) ).
On March 3, 2026, Microbot Medical Inc. said its operations in both the U.S. and Israel remain stable and undisrupted despite current geopolitical tensions in the Middle East, with all employees working as usual and manufacturing partners fully functional. The company emphasized employee safety while maintaining sufficient U.S. inventory and logistics to ensure uninterrupted service and distribution for customers.
Following recent FDA clearance of the LIBERTY system and its limited market release in late 2025, Microbot is concentrating its commercial push on the U.S. market through a Hingham, Mass.-based team. It has added sales staff to expand into new territories and hired a Director of Health Economics and Outcomes Research to support its commercial expansion ahead of a planned full market launch at the Society of Interventional Radiology conference in April 2026.
LIBERTY is described as the only FDA-cleared, single-use, remotely operated robotic system for peripheral endovascular procedures, designed to enable precise vascular navigation while helping reduce radiation exposure and physical strain for clinicians. By confirming operational resilience and strengthening its commercial infrastructure amid regional instability, the company aims to reinforce its market position and reassure stakeholders of its ability to execute its growth strategy.
The most recent analyst rating on (MBOT) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Microbot Medical stock, see the MBOT Stock Forecast page.
More about Microbot Medical
Microbot Medical Inc. is a commercial-stage medical device company focused on transforming endovascular procedures through advanced robotic technology. Its flagship product, the LIBERTY Endovascular Robotic System, is the world’s first FDA-cleared, single-use, remotely operated robotic solution designed to improve precision, efficiency and safety in peripheral vascular interventions.
Average Trading Volume: 2,037,351
Technical Sentiment Signal: Hold
Current Market Cap: $166.6M
For an in-depth examination of MBOT stock, go to TipRanks’ Overview page.